~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Friday, November 27, 2009
Tuesday, November 24, 2009
November 24, 2009 - PhysOrg.com
People with Multiple Sclerosis (MS) feel more than twice as much withheld anger as the general population and this could have an adverse effect on their relationships and health, according to a study published in the December issue of the European Journal of Neurology.
Italian researchers assessed 195 patients with MS, using a range of scales that measure anger, depression and anxiety, and then compared them with the general population.
They were surprised by the results, which showed that while patients experienced almost twice the normal level of withheld anger and exerted low levels of control on their anger, their expressed anger levels were similar to the general population.
This, together with the fact that the elevated withheld anger levels were not related to the severity of the patients' MS, suggests that these inconsistent changes were caused by nervous system damage, rather than an emotional reaction to the stress of the disease.
"We believe that the higher levels of withheld anger shown by the study subjects is due to demyelination, loss of the substance in the white matterthat insulates the nerve endings and helps people receive and interpret messages from the brain" explains lead researcher Dr Ugo Nocentini from the IRCCS S Lucia Foundation in Rome.
"The way we process anger is controlled by complex interconnections between the subcortical and cortical systems, notably the amygdale and basal ganglia and the medial prefrontal cortex. We believe that the demyelination process that causes the root symptoms of MS also disrupts the pathways that control how we deal with withheld anger."
Farmington, CT – Current research suggests that a common oral bacterium may exacerbate autoimmune disease. The related report by Nichols et al, "Unique Lipids from a Common Human Bacterium Represent a New Class of TLR2 Ligands Capable of Enhancing Autoimmunity," appears in the December 2009 issue of The American Journal of Pathology.
Multiple sclerosis (MS), a disease where the immune system attacks the brain and spinal cord, affects nearly 1 in 700 people in the United States. Patients with multiple sclerosis have a variety of neurological symptoms, including muscle weakness, difficulty in moving, and difficulty in speech.
Porphyromas gingivalis, a common oral bacterium in humans, produces a unique type of lipid, phosphorylated dihydroceramides (DHCs), which enhance inflammatory responses. These lipids are also likely produced by bacteria found in other parts of the body including the gastrointestinal tract. To determine if these lipids accentuate immune-mediated damage in autoimmune disease, researchers led by Robert B. Clark and Frank C. Nichols of the University of Connecticut Health Center administered phosphorylated DHCs in a mouse model of MS. The severity of disease was significantly enhanced by the addition of these lipids in a manner that was dependent on activation of the immune system. These data suggest that phosphorylated DHCs from bacteria commonly found in humans may trigger or increase the severity of autoimmune diseases such as multiple sclerosis.
The authors state that "while it is clear that the immune system in most individuals has the potential to attack self-tissues, the "tipping" factors that initiate and propagate autoimmune diseases such as multiple sclerosis in only a subset of individuals remain unknown. Overall, [their] results represent the first description that phosphorylated DHCs derived from common human bacteria are capable of enhancing autoimmune disease." Thus, these lipids may function as "tipping" factors, playing a previously unrecognized role in initiating or exacerbating human autoimmune diseases. In future studies, Dr. Clark and colleagues plan to characterize the effects of phosphorylated DHCs on specific cells of the immune system and to identify how and where these lipids are deposited in tissues throughout the body. In addition to the role of these lipids in triggering and worsening MS, the authors believe that phosphorylated DHCs may have the potential to serve both as new markers of MS disease activity and as new targets for therapeutic intervention.
Giving birth seems to slow the progression of multiple sclerosis (MS), Belgian and Dutch researchers say.
The researchers tracked 330 women with MS for 18 years and found that among those who had children, severe disability took longer to develop.
Writing in the Journal of Neurology, Neurosurgery and Psychiatry, they say previous studies have suggested a worsening of MS just after birth.
But the MS Society said the study was flawed and further research was needed.
MS is a long-term inflammatory condition of the central nervous system.
It affects the transfer of messages from the nervous system to the rest of the body.
Monday, November 23, 2009
The Multiple Sclerosis Society of Canada will be asking Canadian scientists to propose their own research into a procedure that has ignited the hopes of patients in Europe and North America.
The procedure is known as chronic cerebro spinal venous insufficiency, or CCSVI, and involves removing a blockage in the veins that carry blood to and from the brain.
MS Views and News provides information to keep those affected by Multiple Sclerosis informed and up-to-date. Please register at our website to begin receiving our weekly MS Related e-newsletter.
MS Views and News - fournit des informations à conserver ceux qui sont touchés par la sclérose en plaques informés et up-to-date. S'il vous plaît vous inscrire à notre site Web pour commencer à recevoir nos hebdomadaires liés à la SEP e-newsletter.
MS Views and News - proporciona información para mantener a los afectados por esclerosis múltiple informado y al día. Por favor regístrese en nuestra página web para empezar a recibir nuestros semanales relacionadas con la EM e-boletín.
MS Society Canada is helping to take steps to learn more of: Chronic cerebrospinal venous insufficiency (CCSVI) and MS
Keep in mind, all to do with CCVI is Hypothetical - Stuart
Chronic cerebrospinal venous insufficiency (CCSVI) and MS
Overview and FAQ *UPDATED* - November 2009
"As President and CEO of the MS Society, I am aware of the tremendous interest across Canada and around the world caused by the recent news coverage of the CCSVI study. Indeed I share your excitement and hope in the preliminary findings of this study. I also celebrate and respect the integrity of our research funding programs which will continue to ensure that the very best projects are selected and supported. For more detail on this process please link here."
President and chief executive officer
President, Ontario Division
Chronic cerebrospinal venous insufficiency (CCSVI) describes a hypothetical disruption of blood flow in which the venous system is not able to efficiently remove blood from the central nervous system resulting in increased pressure in the veins of the brain and spinal cord which in turn results in damage to these areas. Recent reports have revived the idea of an association between inadequate venous drainage and multiple sclerosis.
The MS Society of Canada is aware of recent reports on the subject of CCSVI that may open up new avenues of research including new therapies for MS. While the early data shows promise, it is important to acknowledge that the concepts surrounding CCSVI and multiple sclerosis are still relatively new and requires replication and validation in much larger, well-designed scientific studies before they can be accepted as established.
The MS Society of Canada is closely monitoring all research related to CCSVI and will post new information on www.mssociety.ca.
Click here to read the FAQ's ( Frequently Asked Questions) on CCSVI
The above link will take you to the MS Society Canada website
Monday, November 23, 2009
Breaking News: MS Society of Canada announces request for research operating grants related to CCSVI and MS
As many of you know, we have received tremendous interest and excitement about the chronic cerebrospinal venous insufficiency (CCSVI) and MS story that appeared on CTV’s W5 this weekend. While Dr. Zamboni is the first to comment that these early results require additional study, it will please you to know that the MS Society of Canada has just confirmed that it will launch a competition to fund operating grants related to CCSVI and MS. To read about this announcement please link here.
In the meantime we recommend that you learn more about CCSVI and MS.
Thanks to your dedication, we will continue to play a leading role in ending MS.
The Stewart found above, is not the Stuart, who posts these messages. This is a new topic for me too, and I am trying as fast as my brain allows, to catch up on this new information.
Zamboni explained that, though multiple sclerosis is an inflammatory neurodegenerative disease of the central nervous system of unknown origin - widely considered to be autoimmune in nature - it is strongly associated with chronic cerebrospinal venous insufficiency.
CTV.ca News Staff
A group of doctors in Italy is investigating a fascinating new treatment for multiple sclerosis, based on a theory that, if proven true, could radically alter the lives of patients.
An investigation by CTV's W5 reveals that this treatment appears to stop the disease from progressing. Patients seen in the documentary relate how, after the simple procedure, their MS symptoms suddenly stopped and, in some cases, they were able to resume normal lives.
The Italian research is asking fundamental questions about the origins of the debilitating condition, whose causes have long remained a mystery.
It's generally assumed that MS is an autoimmune disease in which the body attacks the central nervous system, leading to weakness, extreme fatigue, chronic pain and visual problems.
But what if MS were really a vascular problem? What if it were caused by a structural defect in the veins, one that could be diagnosed and treated before patients become disabled?
That is the radical theory being presented by Dr. Paolo Zamboni, a former vascular surgeon and professor at the University of Ferrara. Zamboni has been conducting research on MS patients and has noticed that almost all of them have malformed or blocked veins in their neck and chest that take blood away from their brains.
He believes that may be contributing to, or even causing, their Multiple Sclerosis.
READ MORE and Watch the Video by clicking here
This article originated a year ago but is now being renewed by CTV in Canada
CTV.ca News Staff
Date: Sun. Nov. 16 2008 10:44 PM ET
An experimental treatment offered at a clinic in Israel may alleviate multiple sclerosis symptoms, even in patients who have an untreatable form of the disease.
Lead researcher Prof. Dimitrios Karussis of Hadassah Medical Center and his colleagues at the Tel Aviv Medical Center have pioneered a procedure whereby they remove a patient's own mesenchymal stem cells - cells in our bone marrow that can turn into heart tissue, bone, cartilage and nerve cells - grow them into large quantities in a laboratory and inject them back into the patient.
Patients who have multiple sclerosis find their immune systems attacking nerve cells, which leads to a range of symptoms from fatigue to severe disability, blindness and even paralysis.
Early data from about 25 patients suggests that the mesenchymal stem cell treatment can repair existing damage to the nerve cells, Dr. Shimon Slavin of the Tel Aviv Medical Center told CTV News.
"The secret is to do the treatment of choice in the early stages of the disease before irreversible changes occur," Slavin said. Researchers are also testing the technique on a number of other neurodegenerative diseases.